AU2018312816B2 - Antibodies that bind EGFR and cMET - Google Patents

Antibodies that bind EGFR and cMET Download PDF

Info

Publication number
AU2018312816B2
AU2018312816B2 AU2018312816A AU2018312816A AU2018312816B2 AU 2018312816 B2 AU2018312816 B2 AU 2018312816B2 AU 2018312816 A AU2018312816 A AU 2018312816A AU 2018312816 A AU2018312816 A AU 2018312816A AU 2018312816 B2 AU2018312816 B2 AU 2018312816B2
Authority
AU
Australia
Prior art keywords
antibody
egfr
variable domain
bispecific antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018312816A
Other languages
English (en)
Other versions
AU2018312816A1 (en
Inventor
Cornelis Adriaan De Kruif
Cecilia Anna Wilhelmina Geuijen
Ton Logtenberg
Robertus Cornelis ROOVERS
Mark Throsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus NV
Original Assignee
Merus NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus NV filed Critical Merus NV
Publication of AU2018312816A1 publication Critical patent/AU2018312816A1/en
Priority to AU2021202874A priority Critical patent/AU2021202874B2/en
Application granted granted Critical
Publication of AU2018312816B2 publication Critical patent/AU2018312816B2/en
Assigned to MERUS B.V. reassignment MERUS B.V. Request for Assignment Assignors: MERUS N.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018312816A 2017-08-09 2018-08-09 Antibodies that bind EGFR and cMET Active AU2018312816B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202874A AU2021202874B2 (en) 2017-08-09 2021-05-06 Antibodies that bind EGFR and cMET

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17185572.9 2017-08-09
EP17185572 2017-08-09
PCT/NL2018/050537 WO2019031965A1 (en) 2017-08-09 2018-08-09 ANTIBODIES THAT BIND EGFR AND CMET

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202874A Division AU2021202874B2 (en) 2017-08-09 2021-05-06 Antibodies that bind EGFR and cMET

Publications (2)

Publication Number Publication Date
AU2018312816A1 AU2018312816A1 (en) 2020-02-27
AU2018312816B2 true AU2018312816B2 (en) 2021-05-27

Family

ID=59579503

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018312816A Active AU2018312816B2 (en) 2017-08-09 2018-08-09 Antibodies that bind EGFR and cMET
AU2021202874A Active AU2021202874B2 (en) 2017-08-09 2021-05-06 Antibodies that bind EGFR and cMET

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202874A Active AU2021202874B2 (en) 2017-08-09 2021-05-06 Antibodies that bind EGFR and cMET

Country Status (27)

Country Link
US (2) US11773170B2 (enExample)
EP (2) EP4553088A3 (enExample)
JP (3) JP2020530028A (enExample)
KR (2) KR20200042485A (enExample)
CN (4) CN118562014A (enExample)
AU (2) AU2018312816B2 (enExample)
BR (1) BR112020002695A2 (enExample)
CA (1) CA3072404A1 (enExample)
DK (1) DK3665198T3 (enExample)
EA (1) EA202090215A1 (enExample)
ES (1) ES3025738T3 (enExample)
FI (1) FI3665198T3 (enExample)
HR (1) HRP20250474T2 (enExample)
HU (1) HUE071182T2 (enExample)
IL (1) IL272461A (enExample)
LT (1) LT3665198T (enExample)
MA (2) MA49846B1 (enExample)
MD (1) MD3665198T3 (enExample)
MX (2) MX2020001432A (enExample)
PH (1) PH12020550055A1 (enExample)
PL (1) PL3665198T3 (enExample)
PT (1) PT3665198T (enExample)
RS (1) RS66708B9 (enExample)
SG (1) SG11202001050PA (enExample)
SI (1) SI3665198T1 (enExample)
TW (1) TWI874301B (enExample)
WO (1) WO2019031965A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
RS66708B9 (sr) * 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
CA3094318A1 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
US11254736B2 (en) * 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
EP3966238A2 (en) 2019-05-09 2022-03-16 Merus N.V. Variant domains for multimerizing proteins and separation thereof
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN112898427B (zh) * 2019-12-03 2023-06-30 同济大学苏州研究院 一种抗c-Met单臂抗体及其制备方法和应用
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
CN119278214A (zh) 2022-03-07 2025-01-07 美勒斯公司 用结合EGFR和cMET的抗体治疗
EP4490189A1 (en) 2022-03-07 2025-01-15 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
CA3256857A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. EGFR/MET ANTIBODIES AND THEIR USES
WO2024109914A1 (zh) 2022-11-24 2024-05-30 江苏恒瑞医药股份有限公司 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
AU2024382013A1 (en) 2023-11-17 2026-06-18 Merus B.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途
TW202608927A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體－藥物偶聯物
TW202608928A (zh) * 2024-04-30 2026-03-01 荷蘭商美勒斯公司 多特異性抗體藥物偶聯物
WO2025247206A1 (zh) * 2024-05-27 2025-12-04 上海迈晋生物医药科技有限公司 特异性结合EGFR和cMET的抗原结合分子、其药物偶联物及其医药用途
CN121045388A (zh) * 2024-05-30 2025-12-02 英百瑞(杭州)生物医药有限公司 针对人c-Met和人EGFR的双特异性抗体及其用途
WO2025247330A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗EGFR×cMet双特异性抗体的药物偶联物及其用途
WO2026145542A1 (zh) * 2024-12-30 2026-07-09 康源博创生物科技(北京)有限公司 一种多肽以及包含其的抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130344093A1 (en) * 2012-06-25 2013-12-26 Regeneron Pharmaceuticals, Inc. Anti-EGFR Antibodies and Uses Thereof
WO2014081954A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. BISPECIFIC EGFR/c-Met ANTIBODIES
WO2015130172A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A7 (fi) 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
NZ243558A (en) 1991-07-15 1994-06-27 Wellcome Found Recombinant primate antibodies and their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101163501A (zh) 2005-02-23 2008-04-16 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2715043C (en) 2008-02-05 2021-02-16 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
MX2011001927A (es) 2008-08-29 2011-04-21 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010284018C1 (en) 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CA2828099A1 (en) 2011-02-24 2012-08-30 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
NO2707391T3 (enExample) 2011-05-13 2018-04-07
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
EP2788381A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
EP2823270B1 (en) 2012-03-09 2022-05-04 Promega Corporation pH SENSORS
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
JP2016512533A (ja) 2013-03-14 2016-04-28 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｍｅｔ結合剤およびその使用
CA2908515A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US10208354B2 (en) 2013-08-07 2019-02-19 Universität Zu Köln NRG1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
RS66708B9 (sr) * 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130344093A1 (en) * 2012-06-25 2013-12-26 Regeneron Pharmaceuticals, Inc. Anti-EGFR Antibodies and Uses Thereof
WO2014081954A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. BISPECIFIC EGFR/c-Met ANTIBODIES
WO2015130172A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOSMI SURATI ET AL, "Role of MetMAb (OA-5D5) in c-MET active lung malignancies", EXPERT OPINION ON BIOLOGICAL THERAPY, (2011-12-01), vol. 11, no. 12, doi:10.1517/14712598.2011.626762, ISSN 1471-2598, pages 1655 - 1662 *
PAN D -S ET AL, "Binding characteristic of fully human anti-EGFR monoclonal antibody to EGFR in skin tissues of different species of animals", CHINESE JOURNAL OF NEW DRUGS (2012-01), vol. 21, no. 1, ISSN 1003-3734, pages 26 - 30 *
R CASTOLDI ET AL, "A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity", ONCOGENE, (2013-07-01), vol. 32, no. 50, pages 5593 - 5601 *
S. L. MOORES ET AL, "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors", CANCER RESEARCH, US, (2016-05-23), vol. 76, no. 13, pages 3942 - 3953 *

Also Published As

Publication number Publication date
CN118562014A (zh) 2024-08-30
KR20260051470A (ko) 2026-04-16
TWI874301B (zh) 2025-03-01
HRP20250474T1 (hr) 2025-06-06
CN111094351B (zh) 2024-07-12
US20200247892A1 (en) 2020-08-06
EP3665198B1 (en) 2025-01-22
EP3665198B9 (en) 2025-05-21
MD3665198T3 (ro) 2025-08-31
MA49846B1 (fr) 2025-05-30
EP4553088A2 (en) 2025-05-14
EP4553088A3 (en) 2025-12-31
MX2020001432A (es) 2020-03-20
CN119119283A (zh) 2024-12-13
JP2025176063A (ja) 2025-12-03
HUE071182T2 (hu) 2025-08-28
EP3665198A1 (en) 2020-06-17
MA71419A (fr) 2025-04-30
CN111094351A (zh) 2020-05-01
DK3665198T3 (da) 2025-04-28
RS66708B1 (sr) 2025-05-30
SG11202001050PA (en) 2020-03-30
WO2019031965A1 (en) 2019-02-14
MA49846A (fr) 2020-06-17
ES3025738T3 (en) 2025-06-09
MD3665198T2 (ro) 2025-07-31
US20240174756A1 (en) 2024-05-30
IL272461A (en) 2020-03-31
BR112020002695A2 (pt) 2020-08-25
RS66708B9 (sr) 2025-08-29
CA3072404A1 (en) 2019-02-14
LT3665198T (lt) 2025-05-26
JP7736772B2 (ja) 2025-09-09
US12668638B2 (en) 2026-06-30
TW201910354A (zh) 2019-03-16
FI3665198T3 (fi) 2025-04-25
SI3665198T1 (sl) 2025-06-30
CN118580366A (zh) 2024-09-03
HRP20250474T2 (hr) 2025-08-01
KR20200042485A (ko) 2020-04-23
PT3665198T (pt) 2025-05-02
ES3025738T9 (en) 2025-07-10
JP2020530028A (ja) 2020-10-15
PL3665198T3 (pl) 2025-06-09
AU2021202874A1 (en) 2021-06-03
MX2026004785A (es) 2026-06-01
AU2018312816A1 (en) 2020-02-27
EA202090215A1 (ru) 2020-07-01
JP2024029049A (ja) 2024-03-05
FI3665198T9 (fi) 2025-07-02
US11773170B2 (en) 2023-10-03
AU2021202874B2 (en) 2024-10-10
PH12020550055A1 (en) 2020-10-19

Similar Documents

Publication Publication Date Title
US20240174756A1 (en) Antibodies that bind egfr and cmet
US11820825B2 (en) Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor
JP2024079823A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
US20110229463A1 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
HK40125854A (en) Antibodies that bind egfr and cmet
HK40028749A (en) Antibodies that bind egfr and cmet
HK40028749B (en) Antibodies that bind egfr and cmet

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MERUS B.V.

Free format text: FORMER OWNER(S): MERUS N.V.